Observational Study of Women with Endometrial Cancer Receiving Standard Surgery Including Hysterectomy and Sentinel Lymph Node Biopsy
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-08-07
1715
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying women diagnosed with endometrial cancer to understand how often the cancer returns after receiving standard treatment and to monitor the occurrence of lymphedema, a potential side effect. The study focuses on patients with endometrioid adenocarcinoma undergoing surgery including hysterectomy and sentinel lymph node biopsy, aiming to track outcomes over time.
Participants will have surgery involving hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node mapping confirming no malignancy in the lymph nodes. After surgery, those in the study cohort will be followed clinically for relapse with physical exams at post-operative visits for up to 30 months.
During the study, participants will undergo regular physical examinations and clinical follow-up visits to check for cancer recurrence and monitor for lymphedema. Researchers will measure the incidence of pelvic or non-vaginal cancer recurrence within 36 months. Participants will be observed for up to 30 months after surgery, with detailed monitoring of symptoms and outcomes throughout the follow-up period.
CONDITIONS
Brief Title
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
Research Team
N
Nadeem Abu-Rustum, MD
M
Mario Leitao, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histologic diagnosis of endometrioid adenocarcinoma on endometrial biopsy or dilation and curettage
No evidence of disease beyond the uterus on imaging and physical exam
Suitable candidate for surgery including planned hysterectomy, sentinel lymph node biopsy, and bilateral salpingo-oophorectomy
No history of second primary invasive or in situ cancer within past 5 years except non-melanoma skin cancer
Signed informed consent
No prior neoadjuvant chemotherapy or radiotherapy for endometrial cancer
No prior pelvic or abdominal radiotherapy
At surgery, must undergo hysterectomy, bilateral salpingo-oophorectomy unless already performed, and bilateral pelvic sentinel lymph node mapping negative for malignancy
Final pathology showing stage I intermediate-risk endometrioid cancer with specific grade and myometrial invasion criteria
Negative pelvic peritoneal cytology
Adjuvant treatment limited to none or intravaginal radiation only
You will not qualify if you...
Evidence of extrauterine disease, gross lymph node involvement, or cervical invasion on pre-operative imaging or exam (stage > I)
Contraindication for sentinel lymph node mapping
Planned treatment not including surgery with hysterectomy, sentinel lymph node biopsy, and bilateral salpingo-oophorectomy
Intra-operative detection of extra-uterine disease or grossly involved lymph nodes
Any positive pelvic lymph nodes including micrometastasis or isolated tumor cells
Hysterectomy not performed
Bilateral salpingo-oophorectomy not performed unless already done unilateral
Failed unilateral or bilateral sentinel lymph node mapping
Undergoing complete unilateral or bilateral pelvic lymphadenectomy
Undergoing radical type C hysterectomy
Stage IA endometrioid cancer grade 1 or 2 with less than 50% myometrial invasion
Stage IB grade 3 endometrioid cancer
Non-endometrioid histology including serous, clear cell, carcinosarcoma, undifferentiated, or de-differentiated
Empty sentinel lymph node packets
Positive peritoneal cytology
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Single surgical procedure
Participants undergo standard surgery including hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node biopsy as planned.
Follow-up
Duration - Up to 30 months
Participants will be monitored with regular physical exams at post-operative visits to check for cancer recurrence and lymphedema for up to 30 months after surgery.
Regular post-operative visits
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Phase 1a1b Study of NRM-823 Alone and With Immune Checkpoint Inhibitor in Advanced or Metastatic Refractory Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).